Insufficient Evidence of Aducanumab Efficacy, ICER Draft Report Finds
A draft report from the Institute for Clinical and Economic Review, known as ICER, found that there is insufficient evidence to determine whether the investigational therapy aducanumab will provide health benefits to people with Alzheimer’s disease. ICER is an independent non-profit research institute that works to assess the…